About Us

Fresenius Kabi Global at a glance

Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. in the field of biosimilars, we develop product with a focus of autoimmune diseases and oncology.


About us

Fresenius Kabi employs more than 37,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2018, the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the  Fresenius SE & Co. KGaA healthcare group.

Key Figures 

€ in millions 2018 2017
Sales 6,544 6,358
EBITDA1 1,434 1,483
EBIT1 1,139 1,177
Net Income 1,2 742 702
Employees (Dec 31) 37,843 36,380

1 Before special terms
2  Net income attributes to shareholders of Fresenius SE & Co. KGaA